| Cardiovascular and cerebrovascular diseases is a kind of common disease that seriously threatens human beings, especially middle-aged and senior people over50-years-old. Every year the number of people died of cardiovascular and cerebrovascular diseases reaches up to about15million, ranking first among all causes of death. Cardiovascular and cerebrovascular diseases has already become the top killer in the list of causes of death, characteristic of high morbidity, high disability rate, high mortality, high recurrence rate and many complications. Therefore, it is one of the most significant public health problems that we need face and solve for a long time both presently and in the future. As atherosclerotic plaque gets into the unstable state from the stable state, plaque ruptures, and enhanced platelet aggregation and adhesion bring about thrombogenesis and angiemphraxis, regarded as a common pathological basis on acute cardiovascular and cerebrovascular diseases. As a result, it is of great importance and interest in atherosclerosis (AS) prevention research in the field scientific research all along.Researches in recent years have confirmed that AS is a complicated pathological process with many regulation factors to participate in and many abnormal genes to adjust to. Lipid metabolic disorders are proved to be one of the major risk factors of AS. Numerous studies have confirmed that levels of LDL-C, TC and ApoB is positively correlated to AS while levels of HDL-C and ApoA I is negatively correlated to it. Improving the lipid metabolism especially lowering LDL-C can help alleviate AS. As researches on AS progress step by step, some inflammatory chemical factors and cytokines are detected gradually. It was not until1999that Professor Ross put forward explicitly that AS is a chronic inflammatory disease. At every stage of AS development from atherosclerotic plaque formation to plaque rupture and thrombogenesis, there are quite a few inflammatory cells and mediators involved in the process. It is known as inflammation theory. Through active measures to intervening in inflammatory factor, genesis and progress of AS lesions can be restrained.There is no name of AS in Traditional Chinese Medicine (TCM). On the basis of manifestation of AS at middle and advanced stage and different disease location, AS involves headache, vertigo, chest obstruction, angina pectoris, stroke, etc. Although we don’t reach a consensus on etiology and pathogenesis of AS in the field of TCM, we have the same opinion that AS results from deficiency of Ben and repletion of Biao which is blood stasis and phlegm. Pathogenesis of blood stasis runs through the entire process of AS and therapy for activating blood circulation in TCM is just established to aim at the blood stasis syndrome. Valuable experience has been accumulated in treating AS by applying drugs for invigorating blood circulation and eliminating stasis which have an exact therapeutic effect actually. Researches have demonstrated that single herb and compound prescriptions of drugs for invigorating blood circulation and eliminating stasis can delay even reverse the process of AS in the matter of lipid-lowering, anti-inflammation, inhibition of the aggregation and adhesion of platelet, inhibition of smooth muscle cell proliferation and regulation of vascular remodeling. The experiment is specially performed for AS prevention and treatment. The remodeling and drug administration proceed simultaneously to study the effect of Xiongshao Capsule on Anti-atherosclerosis in terms of serum lipid, and inflammation factors.Objective:To study the influence of Xiongshao Capsule on serum lipid levels and relevant inflammation factors of rabbit model of high fat diet-induced AS through animal experiment.Methods:(1)60male New Zealand Rabbits are divided into6groups at random:blank control group, model group, Xiongshao Capsule low dose group, Xiongshao Capsule middle dose group, Xiongshao Capsule high dose group, and simvastatin group. Except blank control group, every rabbit is fed by high fat diet for12weeks in order to copy rabbit model of AS. Blood samples are drawn from auricular veins both before and12weeks after the start of experiment to determine total cholesterol(TC), triglyceride(TG), high-density lipoprotein(HDL), low-density lipoprotein(LDL), very-low-density lipoprotein(VLDL), apolipoprotein AI (ApoAI), apolipoproteinB100(ApoB100), high-sensitivity C-reactive protein(HSCRP), Interleukin-2(IL-2), Intcrleukin-6(IL-6), tumor necrosis factor-a (TNF-a).(2) Compare the changes before and after the experiment and changes between groups on weight, serum lipid levels and relevant inflammation factors. Then the data are analyzed by SPSS17.0.Results:(1) Continual High-fat diet for12weeks can induce obvious weight gain of all groups (P<0.01). Weight in Xiongshao Capsule of low and high dose group and simvastatin group is more than that in blank control group to some extent (P<0.01or P<0.05).(2) After12week of molding, TC, LDL, ApoAI and APOB100in every group increase to some extent (P<0.05or P<0.01). VLDL and HDL in every group except blank control group increase obviously (P<0.01). There is no obvious change of TG in every group before and after experiment. In comparison with blank control group, TC, LDL, VLDL, HDL and ApoB100increase to some extent (P<0.01or P<0.05). TG in Xiongshao Capsule of low dose group and ApoAI in simvastatin group increase (P<0.05). In comparison with model group, LDL in Xiongshao Capsule of middle dose group and ApoAI in simvastatin group increase (P<0.05). By advanced comparision among4groups with drugs, ApoAI in simvastatin group is dramatically more than that in Xiongshao Capsule of middle dose group (P<0.01) and ApoAI in Xiongshao Capsule of high dose group is more than that in Xiongshao Capsule of middle dose group (P<0.05)(3) After12weeks of molding, HSCRP in every group and IL-6in every group except Xiongshao Capsule of high dose group increase to some extent (P<0.05or P<0.01). In comparison with model group, TNF-α, IL-2and IL-6in Xiongshao Capsule of high dose group decrease(P<0.05).Conclusion:(1) Xiongshao Capsule of high dose may have the tendency of improving ApoAI. And there is no different effect on serum lipid between Xiongshao Capsule and simvastatin and both didn’t obviously lower serum lipid. As a result, we can’t deny the effect of Xiongshao Capsule on blood lipid metabolism.(2) Xiongshao Capsule plays a role in lowering TNF-α, IL-2and IL-6. Finally we can draw a conclusion that Xiongshao Capsule may inhibit AS in terms of anti-inflammatory. |
PDF Full Text Request